Compare AbCellera Biologics Inc (ABCL) vs TORM plc (TRMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs TORM plc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while TORM plc trades at $28.97 (market cap $2.87B). The key difference: TORM plc is the larger of the two by market cap, and TORM plc pays a 9.87% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TRMD | |
|---|---|---|
Market Cap | $2.35B | $2.87B |
Sector | Health | Technology |
52-Week High | $8.12 | $34.87 |
52-Week Low | $2.78 | $17.33 |
Enterprise Value | $1.99B | $3.76B |
Dividend Yield | — | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TRMD trades at $27.99, up 1.05% today, with neutral technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.21 and P/B of 1.26, supported by robust profitability including 24.41% net margin and 15.62% ROE. Recent earnings showed mixed results with Q4 2025 beat but Q1 2026 miss, while Q2 2026 expectations are set at $3.3 EPS. The company maintains strong cash generation with $498.9M operating cash flow in 2025 and recently declared a $0.70 dividend.
Outlook remains positive with 100% analyst buy ratings and improving 2026 revenue guidance to $1.4B. Key opportunities include undervaluation relative to peers and strong dividend yield near 9%. Risks include earnings volatility from tanker market fluctuations and negative net cash flow trends. The stock presents value for income-focused investors despite cyclical industry exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
